Somatic Stem Cells in Leiomyomas?
|Leiomyomas||Genetic: Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Identification and Characterization of Putative Leiomyoma Stem Cells.|
- Formation and growth of human leiomyomas [ Time Frame: 36 months ]Assessment of pluripotent potential from isolated cells responsible for the formation and growth of human leiomyomas.
Biospecimen Retention: Samples With DNA
|Study Start Date:||April 2012|
|Study Completion Date:||December 2015|
|Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Patients with symptomatic uterine fibroids.
Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
Genetic: Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.
The organ of interest in our study is the myometrium, a muscle layer of the uterus located between the perimetry and the endometrium.
The investigators try to identify, locate and characterize the myometrial stem cell population in the uterine fibroids by isolation of "Side Population" by flow cytometry. Once the investigators achieve the purposes to set out, the investigators would try to maintain "in vitro" stem cell population isolated from myometrial fibroids, for further endocrine characterization. Finally, the investigators would try to induce the formation of fibroids in murine models as a first step to demonstrate that the origin of these formations is due to the abnormal proliferation of myometrial adult stem cells. The results of this study will allow the identification of the cell population in the fibroids. The investigators also can being able to compare with the myometrium in order to establish a relationship that helps us to understand more about the pathophysiology of this disease, using these stem cells as targets therapy in the treatment of this myometrium condition.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01592903
|Valencia, Spain, 46015|
|Principal Investigator:||Carlos Simon, MDPhD||Igenomix|